AP
NVO

Archon Partners’s Novo Nordisk NVO Stock Holding History

Archon Partners’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-140,000
Closed -$9.66M – 41
2025
Q2 		$9.66M Buy
140,000
+50,000
+56% +$3.4M 1.11% 30
2025
Q1 		$6.25M Buy
+90,000
New +$7.43M 0.76% 31
2013
Q3 		– Sell
-444,000
Closed -$6.88M – 69
2013
Q2 		$6.88M Buy
+444,000
New +$7.39M 2.35% 23

Other funds holding NVO

Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Archon Partners's NVO Position: Q3 2025 in Review

Archon Partners sold out of Novo Nordisk (NVO) in Q3 2025, closing a stake of 140,000 shares — an estimated $9.66M sold.

Archon Partners first reported a position in NVO in Q2 2013 and held it in 3 quarters. The position peaked at $9.66M in Q2 2025. 1,397 funds tracked by Wall St. Rank hold NVO as of Q3 2025.

  • Archon Partners reported no remaining Novo Nordisk position as of Q3 2025 after selling out during the quarter.
  • Archon Partners sold 140,000 Novo Nordisk shares in Q3 2025, an estimated $9.66M.
  • Archon Partners first reported a position in Novo Nordisk in Q2 2013 and held it in 3 quarters.
  • Archon Partners's Novo Nordisk position peaked at $9.66M in Q2 2025.
  • 1,397 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2025.

Based on Archon Partners's 13F filing for Q3 2025, filed 14 Nov 2025.